NPY1R and pachyonychia congenita: These results show that pharmacological NPY1R inhibition using BIBO3304 reduces PC metastasis to the liver, highlighting the possibility that NPY1R inhibition could represent a novel future therapeutic strategy to counteract PC metastasis in combination with standard-of-care therapies, such as gemcitabine/Abraxane or FOLFIRINOX (5, 6).